Table 1.
Summary of clinical data. Patients are grouped according to treatment characteristics as indicated on the left side. All groups include seropositive and seronegative patients of different ages and disease duration. All except for one patient were female. DAS28 and SDAI values are colored for each patient from highest (red) to lowest (blue). DAS28 response is indicated according to EULAR criteria [32] and remission indicated when DAS28 was below 2.6 at T3. SDAI response is given in percent reduction and was minor (MiR; >50% and <70%), moderate (MoR; >70% and <85%) or major (MaR; >85%) with remission when SDAI < 3.3. f: female; m: male; BMI: body mass index; RF: rheumatoid factor; ACPA: anti-citrullinated-peptide-antibodies; Pred: prednisolone; cDMARD: conventional disease modifying antirheumatic drug; bDMARD: biological DMARD; DAS28: disease activity score 28-joint count; SDAI: simplified disease activity index for RA; MTX: methotrexate; LEF: leflunomide; SSZ: sulfasalazine; HCQ: hydroxychloroquine; TOC: tocilizumab; ETN: etanercept; CZP: certolizumab-pegol; ABT: abatacept; ADA: adalimumab; RTX: rituximab; NR: DAS28 non-response; MR: DAS28 moderate response; GR: DAS28 good response; SR: DAS28 stable remission.
| Patient | Age | Gender | BMI | Diseased | RF | ACPA | Pred | Current Therapy | Previous Therapy | DAS28 | DAS28 Response | DAS | SDAI | SDAI Response | SDAI | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (Years) | (Years) | (U/L) | (U/L) | (mg/d) | cDMARD | bDMARD | cDMARD | bDMARD | T0 | T1 | T2 | T3 | T1 | T2 | T3 | Best | Remission | T0 | T1 | T2 | T3 | T1 | T2 | T3 | Best | Remission | ||||
| no immunosupressive medication | RA_01 | 49 | f | 32.4 | 6.9 | 59.3 | 184 | MTX | 4.06 | 4.08 | 4.10 | 3.17 | NR | NR | MR | MR | 11.3 | 11.8 | 9.6 | 7.3 | 4% | −15% | −35% | |||||||
| RA_03 | 54 | f | 27.2 | 0.3 | 14 | 0.9 | 4.46 | 4.02 | 3.18 | 2.50 | NR | GR | GR | GR | Remission | 15.1 | 12.9 | 10.0 | 7.5 | −15% | −34% | −50% | MiR | |||||||
| RA_09 | 22 | f | 17.2 | 21.2 | 14 | 0.5 | 5.54 | 4.63 | 4.49 | 3.98 | MR | MR | MR | MR | 41.4 | 41.4 | 41.1 | 36.3 | 0% | −1% | −12% | |||||||||
| RA_13 | 61 | f | 24.0 | 11.3 | 49.9 | 300 | MTX | TOC | 4.97 | 5.76 | 5.68 | 6.64 | NR | NR | NR | NR | 24.3 | 33.5 | 27.3 | 46.0 | 38% | 12% | 89% | |||||||
| Prednisolone | RA_08 | 65 | f | 20.0 | 5.1 | 935.4 | 272 | 2 | MTX | 4.42 | 3.92 | 3.63 | 3.24 | NR | MR | MR | MR | 30.8 | 21.7 | 22.9 | 19.4 | −30% | −26% | −37% | ||||||
| RA_16 | 41 | f | 25.4 | 0.9 | 14 | 0.4 | 2.5 | 2.32 | 2.18 | 2.47 | 2.18 | SR | SR | SR | SR | Remission | 6.3 | 4.6 | 5.7 | 4.9 | −27% | −10% | −22% | |||||||
| RA_12 | 31 | f | 22.7 | 7.3 | 70.6 | 212 | 5 | 3.13 | 2.75 | 1.99 | 2.48 | NR | MR | MR | MR | Remission | 13.0 | 7.4 | 6.0 | 6.3 | −43% | −54% | −52% | MiR | ||||||
| RA_18 | 65 | f | 20.5 | 4.6 | 14 | 340 | 5 | 4.98 | 4.47 | 3.98 | 3.17 | NR | MR | GR | GR | 26.3 | 22.2 | 18.1 | 14.8 | −16% | −31% | −44% | ||||||||
| RA_19 | 70 | f | 25.1 | 6.6 | 14 | 0.4 | 5 | MTX | 5.96 | 5.37 | 4.64 | 4.37 | NR | MR | MR | MR | 33.5 | 23.5 | 21.3 | 19.7 | −30% | −36% | −41% | |||||||
| cDMARD ± prednisolone | RA_05 | 77 | m | 20.6 | 36.1 | 31.3 | 67 | MTX | 5.04 | 3.23 | 2.66 | 2.58 | MR | GR | GR | GR | Remission | 19.5 | 8.8 | 12.2 | 5.6 | −55% | −37% | −71% | MoR | |||||
| RA_04 | 50 | f | 21.5 | 1.7 | 31.3 | 340 | 5 | MTX | 1.82 | 1.25 | 1.05 | 0.49 | SR | MR | GR | GR | Remission | 3.6 | 2.8 | 2.7 | 0.1 | −22% | −25% | −97% | MaR | Remission | ||||
| RA_17 | 52 | f | 20.8 | 8.6 | 104 | 285 | 5 | LEF | MTX | 4.78 | 4.70 | 3.21 | 3.75 | NR | MR | MR | MR | 24.7 | 23.6 | 18.1 | 17.6 | −4% | −27% | −29% | ||||||
| RA_11 | 72 | f | 27.8 | 16.1 | 195.1 | 275 | 6 | MTX | 5.20 | 5.03 | 4.45 | 3.96 | NR | MR | MR | MR | 28.4 | 20.8 | 14.0 | 10.5 | −27% | −51% | −63% | MiR | ||||||
| RA_02 | 63 | f | 32.9 | 14.9 | 14 | 0.4 | 10 | MTX | ABT RTX |
7.05 | 6.26 | 6.70 | 6.18 | NR | NR | NR | NR | 49.9 | 36.8 | 44.9 | 41.2 | −26% | −10% | −17% | ||||||
| bDMARD ± prednisolone | RA_10 | 53 | f | 25.5 | 35.2 | 600 | 12.4 | TOC | MTX, SSZ, HCQ |
ADA ETN |
2.64 | 1.93 | 1.41 | 1.55 | MR | GR | MR | GR | Remission | 11.1 | 7.6 | 3.2 | 2.6 | −32% | −71% | −77% | MoR | Remission | ||
| RA_07 | 52 | f | 39.9 | 0.9 | 151 | 60 | 5 | ETN | MTX | 5.83 | 4.57 | 4.31 | 2.93 | MR | MR | GR | GR | 38.3 | 24.4 | 21.2 | 7.1 | −36% | −45% | −81% | MoR | |||||
| RA_14 | 34 | f | 23.9 | 20.3 | 119.7 | 30 | 15 | CZP | 3.97 | 5.16 | 3.89 | 3.61 | NR | NR | NR | NR | 19.3 | 27.6 | 19.4 | 16.3 | 43% | 1% | −16% | |||||||
| bDMARD & MTX & prednisolone | RA_20 | 61 | f | 26.1 | 25.6 | 14 | 0.8 | 5 | MTX | ABT | 4.93 | 5.06 | 4.26 | 3.49 | NR | MR | MR | MR | 24.7 | 25.1 | 15.4 | 14.5 | 2% | −38% | −41% | |||||
| RA_06 | 22 | f | 25.5 | 6.1 | 240.4 | 2.6 | 7.5 | MTX | ADA | LEF | CZP TOC |
3.24 | 2.62 | 1.93 | 1.96 | MR | GR | GR | GR | Remission | 11.4 | 6.0 | 5.5 | 1.7 | −47% | −52% | −85% | MaR | Remission | |
| RA_15 | 30 | f | 22.3 | 1.9 | 14 | 136 | 10 | MTX | ETN | ADA ABT |
3.45 | 3.17 | 2.51 | 2.23 | NR | MR | GR | GR | Remission | 13.6 | 11.1 | 6.1 | 6.0 | −18% | −55% | −56% | MiR | |||